Business
Patent Grants in Japan & China for TYK2 Inhibitors
Patent Grants in Japan & China for TYK2 Inhibitors.
About this update from Sareum Holdings Plc
[{"type":"text","content":"\n \nRNS Number : 6985Z Sareum Holdings PLC 19 December 2017 \n\n\n\n\n\n(AIM: SAR)\n\n\n19 December 2017\n\n\n\n\nSAREUM HOLDINGS PLC\n(\"Sareum\" or \"the Company\")\nPatent Grants in Japan and China for Sareum's TYK2 Inhibitors\nSareum (AIM: SAR), the specialist cancer drug discovery and development business, is pleased to announce that the Japanese Patent Office has granted a patent for inventions associated with Sareum's TYK2 Kinase Inhibitor Programme, and that the Chinese Patent Office has issued notification that such a patent will be granted subject to certain formalities being completed.\nThis patent* describes compounds that inhibit JAK kinase enzyme function, in particular TYK2 kinase. It also describes the use of these compounds in the treatment of disease mediated by these kinase enzymes, including autoimmune diseases such as multiple sclerosis, psoriasis and inflammatory bowel disease. \nThe granting of the Japanese patent and the imminent granting of the Chinese patent mean that Sareum will have approved patent protection in Japan and China for its TYK2 inhibitor programme. Similar patent protection in Europe was announced on 10 November 2014 and the Company expects that similar patents will be granted in other major markets, including the USA, in due course.\n* Japanese Patent no. 6239118, Chinese Patent Application no. 201380080517X\nSareum's CSO, Dr John Reader, commented: \"The granting of this patent in Japan and China is a key step in securing the protection of the intellectual property for our TYK2 programme in all major markets and it enhances the value of this programme as we progress discussions with potential licensing partners.\"\nFor further information, please contact:\n\n\n\n\nSareum Holdings plc\n\n\n \n\n\n\n\nTim Mitchell\n\n\n01223 497 700\n\n\n\n\nWH Ireland Limited (Nominated Adviser and Co-Broker)\n\n\n \n\n\n\n\nChris Fielding / James Sinclair-Ford\n\n\n020 7220 1666\n\n\n\n\nHybridan LLP (Co-Broker)\n\n\n \n\n\n\n\nClaire Noyce\n\n\n020 3764 2341\n\n\n\n\nCitigate Dewe Rogerson (Media enquiries)\n\n\n \n\n\n\n\nShabnam Bashir/ Mark Swallow/ David Dible\n\n\n020 7282 9571\n\n\n\n\nNotes for editors: \nSareum is a specialist drug discovery and development company delivering targeted small molecule therapeutics, focusing on cancer and autoimmune disease, and gen...